Oncology and Hematology

Our strong oncology portfolio provides cancer patients with a broad range of innovative therapies and practical solutions.

• Our efforts to discover and develop innovative approaches for the treatment of cancer have produced breakthrough medicines such as the leukemia therapy Gleevec/Glivec (imatinib) and the breast cancer agent Femara (letrozole) as well as Zometa (zoledronic acid) for the treatment of bone cancers. Sandostatin LAR (octreotide) is for the treatment of acromegaly, a disorder caused by overproduction of growth hormone, and other tumors. Tasigna (nilotinib) was recently launched as a next generation treatment for chronic myeloid leukemia (CML).
  
• Our leading compounds in development are RAD001 (everolimus) for various tumors and SOM230 (pasireotide) for Cushing’s disease.

Visit Novartis Oncology websites:

US

Global